Efficacy and safety of botulinum toxin a injection into urethral sphincter for underactive bladder.
Botulinum toxin type A
Residual urine volume
Underactive bladder
Urethral sphincter
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
05 Jul 2019
05 Jul 2019
Historique:
received:
02
02
2019
accepted:
26
06
2019
entrez:
7
7
2019
pubmed:
7
7
2019
medline:
2
1
2020
Statut:
epublish
Résumé
The aim of this retrospective study was to evaluate the clinical efficacy and safety of botulinum toxin type A (BTX-A) injection into the urethral sphincter to treat patients with underactive bladder (UAB). From September 2012 to December 2018, 35 patients with UAB who presented with dysuria were treated with BTX-A (Prosigne®, Lanzhou Biological Products, Lanzhou, China). All patients were evaluated using the International Continence Society standard for video-urodynamic examination before and 1 month after treatment. The index includes maximum urinary flow rate, detrusor leak point pressure, and maximum urethral pressure. Post-voiding residual urine volume was measured using ultrasound before, one and 3 months post injection. After 1 month of treatment, the maximum flow rate increased from 2.5 ± 1.1 ml/s to 6.6 ± 1.7 ml/s (P < 0. 05). The maximum urethral pressure decreased from 73.5 ± 5.8 cmH The results suggest that Prosigne® injection into the urethral sphincter is an effective, safe, and inexpensive way to treat UAB.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this retrospective study was to evaluate the clinical efficacy and safety of botulinum toxin type A (BTX-A) injection into the urethral sphincter to treat patients with underactive bladder (UAB).
METHODS
METHODS
From September 2012 to December 2018, 35 patients with UAB who presented with dysuria were treated with BTX-A (Prosigne®, Lanzhou Biological Products, Lanzhou, China). All patients were evaluated using the International Continence Society standard for video-urodynamic examination before and 1 month after treatment. The index includes maximum urinary flow rate, detrusor leak point pressure, and maximum urethral pressure. Post-voiding residual urine volume was measured using ultrasound before, one and 3 months post injection.
RESULTS
RESULTS
After 1 month of treatment, the maximum flow rate increased from 2.5 ± 1.1 ml/s to 6.6 ± 1.7 ml/s (P < 0. 05). The maximum urethral pressure decreased from 73.5 ± 5.8 cmH
CONCLUSIONS
CONCLUSIONS
The results suggest that Prosigne® injection into the urethral sphincter is an effective, safe, and inexpensive way to treat UAB.
Identifiants
pubmed: 31277635
doi: 10.1186/s12894-019-0490-4
pii: 10.1186/s12894-019-0490-4
pmc: PMC6611008
doi:
Substances chimiques
Neuromuscular Agents
0
Botulinum Toxins, Type A
EC 3.4.24.69
prosigne
EC 3.4.24.69
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
60Références
Int Urol Nephrol. 2011 Sep;43(3):655-62
pubmed: 21110094
Biologics. 2012;6:299-306
pubmed: 22977301
Int Urogynecol J. 2015 Jul;26(7):1021-6
pubmed: 25690160
Int Urol Nephrol. 2016 Jun;48(6):919-30
pubmed: 26931421
Toxins (Basel). 2016 Apr 21;8(4):120
pubmed: 27110822
Neurourol Urodyn. 2017 Jun;36(5):1243-1260
pubmed: 27917521
Mov Disord. 2017 Aug;32(8):1131-1138
pubmed: 28639368
J Formos Med Assoc. 2018 Mar;117(3):178-184
pubmed: 28969876
Medicine (Baltimore). 2018 Jan;97(3):e9610
pubmed: 29504988
Toxins (Basel). 2018 May 10;10(5):
pubmed: 29748471
Toxins (Basel). 2018 Sep 13;10(9):
pubmed: 30217070
J Urol. 1988 May;139(5):919-22
pubmed: 3361663